Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology

Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) announced that the Chinese National Intellectual Property Administration issued Patent No. ZL2020800215666, covering key aspects of its breast cancer vaccine technology and extending IP protection in China into the 2040s.

The vaccine, invented at Cleveland Clinic and exclusively licensed to Anixa, targets human α-lactalbumin to prevent and treat certain breast cancers. Anixa said this patent strengthens its global patent estate and supports future international development and commercialization. A Phase 1 trial has been completed and full results will be presented on Dec 11, 2025 at the San Antonio Breast Cancer Symposium.

Positive

• Chinese patent issued (ZL2020800215666) extending protection into the 2040s
• Exclusive license from Cleveland Clinic for the α-lactalbumin vaccine technology
• Phase 1 clinical trial completed with full results scheduled for Dec 11, 2025

Negative

• Clinical efficacy details not disclosed; full Phase 1 results pending Dec 11, 2025

Insights

IP & Clinical Strategy Analyst

Chinese patent issuance extends breast cancer vaccine IP into the 2040s and supports Anixa's international development pathway.

Anixa Biosciences gains formal IP protection in China via Patent Number ZL2020800215666 for its breast cancer vaccine technology, which is licensed from Cleveland Clinic. The patent explicitly covers the vaccine approach targeting human α-lactalbumin and, per the release, complements a broader, expanding global patent estate that the company says extends foundational protection into the 2040s.

The business mechanism is straightforward: strengthened patent coverage in a high-incidence market creates legal exclusivity that can underpin future licensing, regional partnerships, or direct commercialization efforts. This reduces a key execution risk—freedom to operate—in China, subject to the usual limitation that a patent grants exclusionary rights but does not by itself assure regulatory approval or commercial uptake.

Dependencies and risks remain clear and grounded in the text: clinical development progress and public disclosure matter. The release notes a completed Phase 1 trial and a planned full data presentation at the San Antonio Breast Cancer Symposium on Dec 11, 2025, which is a concrete near-term milestone to monitor. Regulatory acceptance in China, partner interest, and later‑stage clinical outcomes will determine commercial value; the patent strengthens negotiating leverage but does not alter clinical or regulatory risk.

Watch the Dec 11, 2025 data presentation closely and any subsequent statements about regulatory filings or partnership discussions tied to China or other jurisdictions covered into the 2040s. Expect patent-driven strategic options (licensing, regional partnerships) to surface if clinical data support further development.

Expands global intellectual property coverage in markets with high breast cancer incidence

New patent will provide IP protection of Breast Cancer Vaccine in China into 2040

SAN JOSE, Calif., Oct. 20, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Chinese National Intellectual Property Administration (CNIPA) has issued Patent Number ZL2020800215666, covering key aspects of the Company's breast cancer vaccine technology.

Anixa's breast cancer vaccine, developed in collaboration with Cleveland Clinic, represents a novel approach to the prevention and treatment of breast cancer. Anixa's vaccine is based on immunizing against human α-lactalbumin, a protein associated with lactation that is aberrantly expressed in certain types of breast cancer. This "retired" protein vaccine strategy aims to selectively prime the immune system to prevent tumor formation while avoiding harm to normal tissue. The vaccine was invented at Cleveland Clinic, and this patent—along with others related to this technology—has been exclusively licensed to Anixa Biosciences.

This patent issuance builds upon the Company's broad and expanding intellectual property portfolio, extending foundational patent protection for the breast cancer vaccine program into the 2040s in multiple jurisdictions throughout the world. By reinforcing its global patent estate, Anixa is laying the groundwork for future international development and commercialization strategies.

"This newly issued patent further demonstrates the novelty and potential of our breast cancer vaccine," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "As we continue advancing clinical development in the U.S., this patent further strengthens our ability to pursue strategic global opportunities in regions with a high incidence of breast cancer."

A Phase 1 clinical trial of Anixa's breast cancer vaccine has been recently completed and Cleveland Clinic will present full clinical results at the San Antonio Breast Cancer Symposium on December 11, 2025.

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.

Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-issuance-of-chinese-patent-covering-breast-cancer-vaccine-technology-302588477.html

SOURCE Anixa Biosciences, Inc.

FAQ

What did Anixa (ANIX) announce on October 20, 2025 about its breast cancer vaccine patent?

Anixa announced CNIPA issued Patent No. ZL2020800215666, extending Chinese IP protection for its breast cancer vaccine into the 2040s.

How does the new Chinese patent affect Anixa (ANIX) commercialization plans?

Anixa said the patent strengthens its global patent estate and supports future international development and commercialization strategies in high-incidence markets.

What is the mechanism of Anixa's breast cancer vaccine covered by the patent (ANIX)?

The vaccine targets human α-lactalbumin, aiming to prime immunity against tumor-expressed lactation protein while avoiding normal tissue.

Has Anixa (ANIX) reported clinical results for the breast cancer vaccine yet?

A Phase 1 trial has been completed, but full clinical results have not been released and will be presented on Dec 11, 2025.

Is the breast cancer vaccine technology exclusively licensed to Anixa (ANIX)?

Yes; the patent and related inventions were invented at Cleveland Clinic and are exclusively licensed to Anixa.